




TEXAS

GLOBAL LIFE SCIENCE POWERHOUSE

Texas is one of the leading life science states in the country and continues to outpace national growth for the industry. We must continue to focus on strong policy initiatives to grow and strengthen the Texas life sciences industry.



Texas Healthcare & Bioscience Institute
807 Brazos Street, Suite 607
Austin, TX 78701
(512) 708-8424
www.thbi.com



facebook.com/txhbi



[@TXHBI](https://twitter.com/TXHBI)



Texas Healthcare and
Bioscience Institute (THBI)

87TH TEXAS LEGISLATIVE SESSION

LEGISLATIVE PRIORITIES

The Texas life sciences industry is committed to expanding the boundaries of science by discovering, developing, and delivering innovative and needed diagnostics, therapies, and treatments to patients. It is the patient that is the ultimate beneficiary of such advances. The membership of the Texas Healthcare and Bioscience Institute (THBI) is committed to creating an environment where such discoveries flourish and thrive. To that end, THBI supports the following initiatives in the 87th Texas Legislative Session.



PANDEMICS AND INFECTIOUS DISEASES

The pandemic has placed a spotlight on the importance of nurturing bioscience R&D and innovation ecosystems. The current situation illustrates the importance of proactive investment in these ecosystems and the underlying infrastructure and talent that powers them—resources that can be directed toward innovating solutions when a global challenge arises. The capacity of the global biopharmaceutical community to develop and produce diagnostic tests, vaccine candidates, and potential antiviral agents, and to then scale-up their clinical trials, manufacturing, and distribution, is the direct result of investments in the science, technologies, and skilled people that drive innovation.

DID YOU KNOW?

- Texas is home to more than 6,200 life science businesses and over 100,000 employees in related fields
- Clinical Trials in Texas - Texas ranks No. 2 in the nation for number for clinical trials, with approximately 28,600 underway
- Academic R&D Expenditures of nearly \$3.5 billion
- Nearly \$1.4 billion in NIH Funding
- 4,950 patent awards to Texas inventors
- \$2.3 billion in bioscience venture capital investments




PATIENT ACCESS AND INNOVATION

- THBI is committed to safeguarding and preserving timely patient access to new diagnostics, therapies, and treatments while maintaining the integrity of those who utilize the latest innovations to create these products.
- It is critical that all patients fighting diseases have access to needed treatments and cures that allow patients to live longer, healthier, and more productive lives.
- Expansion of the newborn screening program and the inclusion of new conditions to the state’s newborn screening panel within two years of Recommended Uniform Screening Panel (RUSP) approval.
- Rare disease prevalence in Texas – access to therapies
- Vaccination access and education
- Preserve and foster Texas’ investments to continue to grow a productive infrastructure.
- Robust venture capital community to provide critical funding needs to the Texas biopharmaceutical industry
- Diversity, equity, and inclusion across all areas of the life sciences industry.



APPROPRIATE FUNDING FOR HIGHER EDUCATION/RESEARCH

- Encourage the Texas Legislature to support a consistent and transparent mechanism to fund research at our Texas Institutions of Higher Education.
 - Full funding of the Texas Research & Incentive Program (TRIP).
- Encourage the Texas Legislature to meaningfully fund research to ensure national competitiveness and to improve the ability for our Texas Institutions of Higher Education to continue a robust technology transfer system and product development process.
- Passage of tuition revenue bonds (TRBs) for continued progress and growth on university campuses
- Enhanced formula and non-formula funding for Texas’ Health Related Institutions.



CREATE A THRIVING TEXAS LIFE SCIENCES ENVIRONMENT





- Policies to keep Texas’ life science entrepreneurs and small businesses healthy and flourishing.
 - 70% of innovative clinical programs are being led by small companies.
 - 90% of clinical programs ultimately fail to lead to an FDA approval.
 - 92% of biopharmaceutical companies are unprofitable at any given time.
 - 10-15 years is the average time it takes to secure FDA approval of a new medicine at an average cost of \$2.8 billion.
- Continue to support state programs and incentives like:
 - Texas Enterprise Fund (TEF)
 - Governor’s University Research Initiative (GURI)
 - Product Development & Small Business Incubator Loan Program (PDSBI)
 - Cancer Prevention and Research Institute of Texas (CPRIT)
 - R&D Tax Credits
 - Initiatives to further train our next generation of Texas’ biopharmaceutical workforce.
 - Encourage and support STEM education to further prepare future biopharmaceutical scientists.



RESEARCH AND DEVELOPMENT/ MANUFACTURING

- Preserve and foster Texas’ investments to continue to grow a productive infrastructure.
- Texas institutions, investors and innovators are collaborating in unprecedented ways to create innovative treatments and cures and strengthen the Texas economy.
- Protect global supply chain
- Retain Chapter 313

THBI TEAM

-  **Tom Kowalski**, President & CEO
-  **Meredith Armstrong**, Policy Director
-  **Julia Perkins**, Director of Membership & Programming
-  **Virginia Rothenflue**, Director of Operations